2022 Year in Review - Multiple Myeloma
2022 Year in Review - Multiple Myeloma | February 17, 2023
A discrete-choice experiment and best-worst scaling survey identified the most and least important multiple myeloma treatment characteristics to patients and their caregivers.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Cohort B of CARTITUDE-2 evaluated the safety and efficacy of cilta-cel in high-risk patients who experienced early clinical relapse to determine its use in earlier lines of therapy.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.
2022 Year in Review - Multiple Myeloma | February 17, 2023
The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.
